Welcome to our dedicated page for Dbv Technologies S A news (Ticker: DBVT), a resource for investors and traders seeking the latest updates and insights on Dbv Technologies S A stock.
DBV Technologies SA (DBVT) is a clinical-stage biopharmaceutical leader advancing epicutaneous immunotherapy (EPIT) through its innovative Viaskin platform, targeting food allergies with non-invasive precision. This page aggregates all essential updates on the company’s clinical progress, regulatory milestones, and strategic initiatives.
Investors and stakeholders gain centralized access to critical developments including phase trial results, FDA/EMA interactions, and partnership announcements. Each update is curated to provide actionable insights into DBVT’s pioneering work in allergy treatment while maintaining rigorous scientific accuracy.
Key coverage areas include Viaskin efficacy data, patent developments, and manufacturing scalability updates. The resource is designed to help users track the company’s progress from clinical research to potential commercialization without requiring cross-platform monitoring.
Bookmark this page for streamlined tracking of DBV Technologies’ advancements in redefining food allergy management through its unique skin-based immunotherapy approach.
DBV Technologies has released information regarding its total number of voting rights and shares as of September 30, 2024, in compliance with Article 223-16 of the General Regulations of the Autorité des Marchés Financiers. The company, listed on NYSE Euronext Paris with ISIN Code FR 0010417345, reported a total of 96,501,526 shares as of the specified date. The total gross voting rights also stood at 96,501,526, while the total net voting rights were 96,199,467. The net total is calculated by subtracting shares without voting rights from the total number of voting rights attached to shares.
DBV Technologies has completed screening for its VITESSE Phase 3 clinical trial, evaluating the Viaskin® Peanut Patch in peanut-allergic children ages 4-7 years old. The company exceeded its recruitment goal in Q3 2024, closing the screening process earlier than anticipated. The VITESSE trial is the largest immunotherapy clinical trial for this patient population, with over 600 subjects randomized 2:1 across 86 sites globally.
Dr. Pharis Mohideen, Chief Medical Officer, expressed gratitude towards study centers, subjects, and their families for their commitment. The trial aims to evaluate the efficacy and safety of the modified Viaskin Peanut Patch over 12 months. Topline results are expected by Q4 2025. DBV Technologies continues to focus on advancing this program to support a Biologic License Application submission.
DBV Technologies (Euronext: DBV, Nasdaq: DBVT), a clinical-stage biopharmaceutical company, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for Monday, September 9, 2024, in New York City. Daniel Tassé, the company's Chief Executive Officer, will engage in a fireside chat at 3:00 pm ET.
Investors and interested parties can access a live webcast of the presentation through a provided link or via the Events section of DBV Technologies' Investors website. For those unable to attend live, a replay will be available on the company's website for 90 days following the event, offering extended access to the presentation content.
DBV Technologies (DBVT) has released an update on its total number of voting rights and shares as of July 31, 2024. The company reported a total of 96,498,927 shares outstanding. The total gross voting rights also stand at 96,498,927, while the total net voting rights are 96,214,457. This information is provided in compliance with Article 223-16 of the General Regulations of the Autorité des Marchés Financiers. DBV Technologies is listed on the NYSE Euronext Paris under the ISIN Code FR 0010417345.
DBV Technologies (Euronext: DBV, Nasdaq: DBVT), a clinical-stage biopharmaceutical company focused on food allergies and immunologic conditions, has announced the filing of its 2024 Half-Year Report for the semester ended June 30, 2024. The report has been filed with the French market authority, Autorité des Marchés Financiers (AMF).
The 2024 Half-Year Report is now available for consultation or download in French on the company's website (www.dbv-technologies.com) under the Investors/Financial Information section, as well as on the AMF website (www.amf-france.org). Interested parties can also request a free copy by mail or email from DBV Technologies.
DBV Technologies (DBVT) provided updates on its Viaskin Peanut program and reported Q2 2024 financial results. Key highlights:
- VITESSE Phase 3 study enrollment for 4-7 year olds with peanut allergy is on track to complete by Q3 2024
- Submitted labeling proposal to FDA for COMFORT Toddlers study in 1-3 year olds
- Q2 2024 cash balance of $66.2 million, with runway extended into Q1 2025 due to cost-saving measures
- Q2 2024 net loss of $60.5 million or $0.63 per share
- Operating expenses increased to $65.0 million in H1 2024 vs $50.7 million in H1 2023, driven by R&D costs
The company faces substantial doubt about its ability to continue as a going concern beyond Q1 2025 without additional capital.
DBV Technologies (Nasdaq: DBVT), a clinical-stage biopharmaceutical company, has announced it will host a conference call and live audio webcast on Tuesday, July 30th, at 5:30 p.m. ET to discuss its second quarter 2024 financial results and provide a business update. Interested participants can join the call via teleconference or access the live webcast on the company's website. The event details are as follows:
- Teleconference numbers:
United States: +1-877-346-6112
International: +1-848-280-6350
- Webcast: Available on the Investors & Media section of DBV's website
A replay of the presentation will be accessible on the company's website after the event.
DBV Technologies, a clinical-stage biopharmaceutical company listed on Euronext and Nasdaq under the ticker DBVT, released its half-year report on the liquidity contract with ODDO BHF. As of June 30, 2024, the liquidity account held 303,744 DBV Technologies shares and €62,415.60. This is an increase from the initial assets on July 1, 2018, which included 41,159 shares and €432,367.25. Between January 1, 2024, and June 30, 2024, 912 buy transactions and 694 sales transactions were conducted. The total volumes traded were 299,986 shares and €397,966 for purchases, and 219,230 shares and €310,114 for sales.
DBV Technologies, a clinical-stage biopharmaceutical company, will participate in the Goldman Sachs 45th Annual Global Healthcare Conference. CEO Daniel Tassé will engage in a fireside chat on June 10, 2024, at 8:00 am EDT, and attend one-on-one investor meetings. The company focuses on treating food allergies and other immunologic conditions with significant unmet needs. A live webcast and a 90-day replay of the presentation will be available on DBV Technologies’ Investor Relations website.
As of May 31, 2024, the company reported a total of 96,493,078 shares outstanding. The total number of voting rights is 96,493,078, with a net voting right count of 96,236,383. These figures are in accordance with Article 223-16 of the General Regulations of the Autorité des Marchés Financiers.
FAQ
What is the current stock price of Dbv Technologies S A (DBVT)?
What is the market cap of Dbv Technologies S A (DBVT)?
